|
Curis, Inc. (CRIS): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Curis, Inc. (CRIS) Bundle
In the dynamic world of biotechnology, Curis, Inc. (CRIS) emerges as a pioneering force in precision medicine, strategically navigating the complex landscape of cancer therapeutics and innovative molecular therapies. With a razor-sharp focus on developing groundbreaking treatments that could potentially transform patient outcomes, this Cambridge-based biotech firm is pushing the boundaries of scientific innovation, leveraging cutting-edge research and strategic partnerships to advance its mission of combating serious diseases through targeted molecular approaches.
Curis, Inc. (CRIS) - Marketing Mix: Product
Innovative Therapeutics Development
Curis, Inc. specializes in developing targeted molecular therapies for cancer and other serious diseases. As of 2024, the company maintains a focused portfolio of drug candidates in clinical development.
Research and Development Pipeline
| Drug Candidate | Therapeutic Area | Development Stage |
|---|---|---|
| CA-4948 | Hematologic Malignancies | Phase 1/2 Clinical Trial |
| Fimepinostat | Lymphoma | Completed Phase 2 Trial |
Product Specialization
- Small molecule drug candidates
- Antibody-based therapeutic approaches
- Precision medicine targeting
Key Product Characteristics
Molecular Targeting Strategy: Focuses on precision medicine approaches with specific molecular mechanisms.
Pharmaceutical Partnerships
| Partner | Collaboration Focus | Status |
|---|---|---|
| Genentech | Oncology Drug Development | Ongoing Collaboration |
Product Development Metrics
- R&D Expenditure in 2023: $41.4 million
- Number of Active Clinical Programs: 2-3
- Patent Portfolio: Approximately 50-60 patents
Therapeutic Focus Areas
Primary concentration on oncology and hematologic malignancies with precision medicine approach.
Curis, Inc. (CRIS) - Marketing Mix: Place
Headquarters Location
Located at 4 Trebor Road, Cambridge, Massachusetts 02142, United States.
Geographic Market Distribution
| Region | Market Presence | Primary Focus |
|---|---|---|
| North America | Primary Market | Biopharmaceutical Research |
| United States | Dominant Market | Clinical Trials and Drug Development |
Clinical Trial Locations
- Multiple research centers across the United States
- Collaborative hospital networks for clinical studies
- Academic medical research institutions
Distribution Channels
Strategic Partnership Channels:
- Pharmaceutical research collaborations
- Academic research institutions
- Biotechnology development networks
Market Accessibility
| Distribution Method | Target Segment |
|---|---|
| Direct Research Partnerships | Pharmaceutical Companies |
| Clinical Trial Networks | Medical Research Institutions |
Research Infrastructure
Research and Development Locations:
- Cambridge, Massachusetts headquarters
- Collaborative research centers nationwide
- Virtual research collaboration platforms
Curis, Inc. (CRIS) - Marketing Mix: Promotion
Conference Presentations and Research Visibility
Curis, Inc. actively presents research findings at key oncology conferences, including:
| Conference | Frequency | Key Focus |
|---|---|---|
| American Association for Cancer Research (AACR) | Annual | Precision oncology research |
| American Society of Clinical Oncology (ASCO) | Annual | Clinical trial updates |
| European Society for Medical Oncology (ESMO) | Annual | Targeted cancer therapies |
Investor Relations and Scientific Communication
Curis leverages multiple communication channels for brand visibility:
- Quarterly earnings conference calls
- Annual shareholder meetings
- Investor presentations at healthcare conferences
- Press releases detailing scientific advancements
Digital Communication Platforms
| Platform | Purpose | Engagement Metrics |
|---|---|---|
| Corporate Website | Scientific information dissemination | Average monthly visitors: 15,000 |
| Professional networking | Followers: 3,500 | |
| Research updates | Followers: 2,800 |
Clinical Trial Progress Communication
Key Communication Channels for Clinical Trial Updates:
- ClinicalTrials.gov registry submissions
- Scientific journal publications
- Investor presentations
- Company website dedicated research section
Scientific Credibility Enhancement
Peer-reviewed publication metrics for 2023:
| Publication Type | Number of Publications | Impact Factor Range |
|---|---|---|
| Original Research Articles | 7 | 2.5 - 6.8 |
| Review Articles | 3 | 4.2 - 5.9 |
Curis, Inc. (CRIS) - Marketing Mix: Price
Stock Price Performance
As of January 2024, Curis, Inc. (NASDAQ: CRIS) stock price trading range:
- 52-week low: $0.33
- 52-week high: $1.30
- Current market capitalization: Approximately $52 million
Financial Pricing Metrics
| Financial Metric | Value |
|---|---|
| Price to Book Ratio | 0.86 |
| Price to Sales Ratio | 4.12 |
| Enterprise Value | $48.7 million |
Research and Development Expenses
R&D Investment Breakdown:
- Total R&D expenses for 2023: $45.3 million
- Quarterly R&D spending: Approximately $11.3 million
- Percentage of revenue allocated to R&D: 85.6%
Funding Strategy
Curis, Inc. funding sources:
- Equity offerings total in 2023: $22.5 million
- Strategic partnership revenue: $6.8 million
- Cash and cash equivalents as of Q3 2023: $37.2 million
Market Valuation Factors
| Valuation Component | Impact |
|---|---|
| Clinical Trial Progress | Directly influences stock pricing |
| Potential Drug Approvals | Significant market value driver |
| Pipeline Development | Determines investor perception |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.